RESUMO
Antimony compounds are the cornerstone treatments for tegumentary leishmaniasis. The reactivation of herpes virus is a side effect described in few reports. We conducted an observational study to describe the incidence of herpes zoster reactivation during treatment with antimony compounds. The global incidence of herpes zoster is approximately 2.5 cases per 1,000 persons per month (or 30 cases per 1,000 persons per year). The estimated incidence of herpes zoster in patients undergoing antimony therapy is higher than previously reported.
Assuntos
Antimônio/efeitos adversos , Antiprotozoários/efeitos adversos , Herpes Zoster/etiologia , Herpesvirus Humano 3/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antimônio/uso terapêutico , Antiprotozoários/uso terapêutico , Feminino , Herpes Zoster/virologia , Humanos , Leishmaniose Cutânea/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Ativação ViralRESUMO
Antimony compounds are the cornerstone treatments for tegumentary leishmaniasis. The reactivation of herpes virus is a side effect described in few reports. We conducted an observational study to describe the incidence of herpes zoster reactivation during treatment with antimony compounds. The global incidence of herpes zoster is approximately 2.5 cases per 1,000 persons per month (or 30 cases per 1,000 persons per year). The estimated incidence of herpes zoster in patients undergoing antimony therapy is higher than previously reported.